EMEA-000527-PIP03-13

Key facts

Invented name
Lucentis
Active substance
ranibizumab
Therapeutic area
Ophthalmology
Decision number
P/0185/2014
PIP number
EMEA-000527-PIP03-13
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
  • Treatment of macular oedema
  • Treatment of choroidal neovascularisation
Route(s) of administration
Intravitreal use
Contact for public enquiries
Novartis Europharm Limited 
United Kingdom 
E-mail: paediatric.enquiries@novartis.com 
Tel. +41 613241111 
Fax +41 613248001
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating